Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three drugs—bupivacaine, dexamethasone, and dexmedetomidine—used primarily as an adjuvant mixture for regional anesthesia, especially in spinal or peripheral nerve blocks. - **Bupivacaine** is a long-acting local anesthetic that works by blocking voltage-gated sodium channels on neuronal membranes, thereby inhibiting nerve impulse transmission and providing sensory and motor block. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory properties; when used as an adjuvant in regional anesthesia, it prolongs analgesia likely through vasoconstriction (reducing local anesthetic absorption), inhibition of potassium channels on nociceptive C-fibers, and suppression of inflammatory responses. - **Dexmedetomidine** is a highly selective alpha-2 adrenergic receptor agonist that provides sedative and analgesic effects by inhibiting the release of nociceptive neurotransmitters in the central nervous system. The combination has been shown to prolong the duration of sensory block and postoperative analgesia compared to bupivacaine alone or with single adjuvants[1][7][10]. It has been studied for use in procedures such as cesarean section under spinal anesthesia[1][5], knee arthroscopy[8], and various peripheral nerve blocks[10]. The safety profile appears favorable with no significant increase in adverse events reported compared to controls.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + dexamethasone + dexmedetomidine.